Approval of bevacizumab (Avastin) for use in metastatic breast cancer (mBC) has been suspended

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1381, 2011-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab [Avastin; Roche] has been launched in the UK as a first-line treatment for metastatic breast cancer

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Roche's bevacizumab [Avastin] has been approved as a first-line treatment for advanced renal cell cancer in the EU

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

A broad label extension has been approved by the European Commission for bevacizumab [Avastin; Roche].

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Bevacizumab: In First-Line Treatment of Metastatic Breast Cancer

By Scott Lesley J.

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1793-1799

Adis International

Access to resources Recommend Favorite

Bevacizumab: A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer

By Croom Katherine F. Dhillon Sohita

Drugs, Vol. 71, Iss. 16, 2011-11 ,pp. : 2213-2229

Adis International

Access to resources Recommend Favorite